Cargando…

Incentives for orphan drug research and development in the United States

BACKGROUND: The Orphan Drug Act (1983) established several incentives to encourage the development of orphan drugs (ODs) to treat rare diseases and conditions. This study analyzed the characteristics of OD designations, approvals, sponsors, and evaluated the effective patent and market exclusivity l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seoane-Vazquez, Enrique, Rodriguez-Monguio, Rosa, Szeinbach, Sheryl L, Visaria, Jay
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2631478/ https://www.ncbi.nlm.nih.gov/pubmed/19087348 http://dx.doi.org/10.1186/1750-1172-3-33

Ejemplares similares

Disentangling the Cost of Orphan Drugs Marketed in the United States
por: Althobaiti, Hana, et al.
Publicado: (2023)

Drug utilization and cost in a Medicaid population: A simulation study of community vs. mail order pharmacy
por: Valluri, Satish, et al.
Publicado: (2007)

Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs?
por: Rodriguez-Monguio, R., et al.
Publicado: (2017)

Development of a men’s Preference for Testosterone Replacement Therapy (P-TRT) instrument
por: Szeinbach, Sheryl L, et al.
Publicado: (2012)

Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication
por: Balkhi, Bander, et al.
Publicado: (2018)

Predictors of shortages of opioid analgesics in the US: Are the characteristics of the drug company the missing puzzle piece?
por: Rodriguez-Monguio, Rosa, et al.
Publicado: (2021)

Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals
por: Hao, Jing, et al.
Publicado: (2015)

Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
por: Kwon, Christina S., et al.
Publicado: (2018)

Innovation and competition in advanced therapy medicinal products
por: Seoane‐Vazquez, Enrique, et al.
Publicado: (2019)

A Comparative Assessment of Approvals and Discontinuations of Systemic Antibiotics and Other Therapeutic Areas
por: Rodriguez-Monguio, Rosa, et al.
Publicado: (2023)

Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications
por: Zhao, Zhiyao, et al.
Publicado: (2023)

Orphan drug incentives in the pharmacogenomic context: policy responses in the USA and Canada
por: Herder, Matthew
Publicado: (2016)

Orphan drug incentives in the pharmacogenomic context: policy responses in the US and Canada
por: Gibson, Shannon, et al.
Publicado: (2015)

Addressing the needs of Canadians with rare diseases: an evaluation of orphan drug incentives
por: Harris, Emily
Publicado: (2018)

Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies
por: Nguyen, Diane, et al.
Publicado: (2013)

Here Is the Case for the Urge in Administrative Claims Database Research About Overactive Bladder Therapies
por: Szeinbach, Sheryl L., et al.
Publicado: (2008)

Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2021)

Making Sure That Orphan Incentives Tip the Right Way in Europe
por: Horgan, Denis, et al.
Publicado: (2022)

Patient-reported outcome claims in European and United States orphan drug approvals
por: Jarosławski, Szymon, et al.
Publicado: (2018)

Quantifying the persisting orphan-drug shortage public health crisis in the United States
por: Jarosławski, Szymon, et al.
Publicado: (2016)

Estimating the clinical cost of drug development for orphan versus non-orphan drugs
por: Jayasundara, Kavisha, et al.
Publicado: (2019)

Barriers and incentives to orphan care in a time of AIDS and economic crisis: a cross-sectional survey of caregivers in rural Zimbabwe
por: Howard, Brian H, et al.
Publicado: (2006)

Orphan drug: Development trends and strategies
por: Sharma, Aarti, et al.
Publicado: (2010)

Orphans in the Market: The History of Orphan Drug Policy
por: Mikami, Koichi
Publicado: (2019)

The role of globalization in drug development and access to orphan drugs: orphan drug legislation in the US/EU and in Latin America
por: Arnold, Renée J.G., et al.
Publicado: (2015)

Meiosis Research in Orphan and Non-orphan Tropical Crops
por: Bolaños-Villegas, Pablo, et al.
Publicado: (2019)

Documented Orphaned Oil and Gas Wells Across the United States
por: Boutot, Jade, et al.
Publicado: (2022)

The State’s Duty to the Orphan
por: Spratling, Edgar J.
Publicado: (1902)

Cross-national comparative study of orphan drug policies in Saudi Arabia, the United States, and the European Union
por: Balkhi, Bander, et al.
Publicado: (2023)

Association between body mass index and hypertension subtypes in Indian and United States adults
por: Visaria, Aayush, et al.
Publicado: (2020)

Developing a Patient-Directed Policy Framework for Managing Orphan and Ultra-Orphan Drugs Throughout Their Lifecycle
por: Menon, Devidas, et al.
Publicado: (2015)

Challenges in orphan drug development and regulatory policy in China
por: Cheng, Alice, et al.
Publicado: (2017)

Orphan drug development in alpha-1 antitypsin deficiency
por: Trudzinski, Franziska C., et al.
Publicado: (2022)

PIN58 The U.S. International Trade of Medical Products in the COVID-19 Era
por: Preciado, S.M., et al.
Publicado: (2021)

Aligning provider incentives to improve primary healthcare delivery in the United States
por: DeVoe, JE, et al.
Publicado: (2013)

Predictors of orphan drug approval
por: Heemstra, Harald
Publicado: (2010)

Compassionate use of orphan drugs
por: Hyry, Hanna I., et al.
Publicado: (2015)

Orphan drugs: Indian perspective
por: Kumar, Harish, et al.
Publicado: (2017)

To what degree are orphan drugs patient-centered? A review of the current state of clinical research in rare diseases
por: Lanar, Sally, et al.
Publicado: (2020)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
por: Eichler, Hans-Georg, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2756jeo8bc70co86k8b5l137ti